Relationship Between Glycemic Control and Irisin in Type 2 Diabetic Patients With Sarcopenic or Non-sarcopenic Obesity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-02-01

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to compare glycemic control and irisin levels in subjects with diabetes mellitus type 2 with sarcopenic obesity vs non-sarcopenic obesity.

The main questions it aims to answer are:

Is glycemic control worse in diabetic patients with sarcopenic obesity? Are irisin levels higher in patients with non-sarcopenic obesity?

Participants will be asked to:

* Fill in three questionaries on lifestyle
* Perform two physical performance tests

The investigators will collect the following data:

* Anthropometric measurements
* Body composition by bioelectrical impedance analysis.
* Results of routine blood analyses
* Irisin levels by drawing a vial of blood from the antecubital vein

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Relation Between Plasma Irisin Level and Endothelial Dysfunction in Type 2 Diabetes

NCT01877603

Irisin Endothelial Dysfunction Type 2 Diabetes

COMPLETED

Study of Visceral Fat in type2diabetic Patients and Its Relation to Microvascular Complications

NCT06112197

Visceral Fat Insulin Resistance

UNKNOWN

Atheroma Progression and Vulnerability Under Continuous Glucose Monitoring

NCT04559191

Coronary Atherosclerosis

UNKNOWN PHASE4

Irisin Expression and Gene Polymorphism in Type II Diabetic Patients With and Without CAD

NCT04957823

Irisin Gene Polymorphism in Type II Diabetic Patients

COMPLETED

Diet in Elderly With Type 2 Diabetes

NCT05961878

Sarcopenia Sarcopenic Obesity Diabetes Mellitus +2 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be enrolled from our Diabetology Center. Eligible patients will be contacted by phone to be informed of the procedures and to schedule the visit.

The patients will come to the visit bringing the blood analyses they usually bring for the routine diabetologic visit; they will also be fasting for at least 3 hours, and abstaining from smoking and physical activity since the day before. All visits will be performed in the afternoon, at about 4-6 p.m.

Participants will be asked to:

* Fill in three questionaries (SARC-F \[Strength, assistance with walking, rising from a chair, climbing stairs, and falls questionnaire\], IPAQ-EIT \[International Physical Activity Questionnaire validated in the Elderly Italian population\], MEDI-LITE \[Adherence to the Mediterranean diet questionnaire\])
* Perform two physical performance tests (5-times chair stand test and handgrip test).

Anthropometric measurements will be assessed; body composition will be evaluated by bioelectrical impedance analysis. A venous blood draw will be executed for evaluation of irisin levels after signing a written consent form.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia Obesity Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sarcopenic obesity

BMI\>30, bioelectric impedance positive for sarcopenic obesity (FM% \[fat mass percentage\] female \>43%, male \>31% AND SMM/W \[skeletal muscle mass/weight\] female \<28%, male \<37%), any one of the physical performance test positive (5-times chair stand test \>17 s OR handgrip strength test \<35,5 kg for males, \<20 kg for females).

No interventions assigned to this group

Non-sarcopenic obesity

BMI\>30, bioelectric impedance negative for sarcopenic obesity.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diabetes mellitus type 2 diagnosed less than 10 years before
* age \>60 years
* BMI (Body Mass Index) \>30 kg/m2
* eGFR (estimated Glomerular Filtration Rate) \>30 ml/min
* On stable antidiabetic therapy for at least 3 months

Exclusion Criteria

* Insulin or insulin secretagogues use
* Diabetes mellitus type 1, previous diabetic ketoacidosis
* Neuromuscular diseases
* Endocrinopathies that may cause myopathies (hypercortisolism, GH \[growth hormone\] deficiency, acromegaly, adrenal insufficiency, partial hypopituitarism or panhypopituitarism, male hypogonadism, hyperparathyroidism, hypoparathyroidism)
* Severe vit. D deficiency (\<12 ng/ml)
* Hemoglobinopathies
* Prolonged immobilization
* Pathologies with fluid retention (heart failure with NYHA \[New York Heart Association\] class III/IV, severe renal insufficiency, hepatic insufficiency)
* Active tumors in the past 5 years
* Severe arthritis of the knee or hip
* Pacemaker wearer

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No